过敏性哮喘患者新型免疫疗法治疗前后血清嗜酸性细胞阳离子蛋白浓度的变化

A Study of Change in Level of EOS inophilic cell Protein of Allergenic Chronic Asthma Patient with the New Immunotherapy

分别测定发作期及缓解期过敏性哮喘患者新型免疫疗法治疗前后血清嗜酸性粒细胞(EOS)计数、血清嗜酸性细胞阳离子蛋白(ECP)、免疫球蛋白(IgE、IgA、IgM、IgG)含量及肺功能的变化。结果发现:发作期过敏性哮喘患者血EOS、ECP、IgG均明显高于缓解期过敏性哮喘患者和正常健康者(均为P<0.01),发作期及缓解期过敏性哮喘患者治疗前后血EOS、ECP和肺功能(FEV_1、PEFR)均有显著或非常显著性(P<0.05或P<0.01),缓解期过敏性哮喘患者IgA、IgG和IgM浓度较正常健康人明显下降。结论:血清EOS数量与气道高反应性有密切关系,并可作为气道炎症监测及治疗指标。

By determing the number of eosinophilic cells (EOS) of allergenic chronic asthma patients with the new immunotherapy during the period of attack and lysis,the content of eosinophilic cell protein(ECP) and immunoglobulin(IgE,IgA.IgM,IgG),the change of pulmonary function,It shows that EOS,ECP,IgE in allergenic chronic asthma patients during the attack stage have a marked higher level than that in lysis and health ( P <0. 01). During the stage of attack and lysis, EOS, ECP and pulmonary function(FEV1,PETR) in allergenic chronic asthma patients have markedness or high markedness( P <0. 05 or P <0. 01) before and after treatment, while those in lysis have a marked lowerness than that in health in IgA,IgG,and IgM level. Conclusion: The number of EOS has close relationship with pathergy. It can be a predominant measurement and treatment for airway inflammation.